Dear Lauren — K-Beauty Wholesale & B2B

Dear Lauren began in 2018, when our founder turned pharmaceutical drug-delivery technology into a skincare for his three-year-old daughter Lauren, whose severe eczema nothing on the market could calm. That story became the product, and the product became numbers: Forbes Korea's 2025 #1 derma-skincare brand, 17,000+ verified reviews at 4.95/5 (97% five-star), 550,000+ units sold, and a 42% repurchase rate (D2C). For a buyer, this is a brand whose story does the marketing for you — in any market, in any language.

Most brands patent their technology. We don't — a patent is a publication, so we protect ours as a trade secret. SNV(R) is a 200nm triple-capsule delivery system born from pharmaceutical drug-delivery science: in human-skin Franz cell tests, it carried actives past the skin barrier at 63% vs 15% over 24 hours — about 4x deeper. Human clinical trials followed: up to +857% in deep-layer hydration and a 0.000 skin-irritation index. Already exporting via an official Taiwan distributor and a U.S. subsidiary, this is a formula competitors cannot reverse-engineer — and a margin you can defend.

Regulatory work is where most K-beauty deals stall — so we did it first. EU: CPNP registration of the Intensive line completes by early September 2026; additional lines we register in-house. US: our subsidiary Bilico LLC (New Jersey) is the importer of record — customs and fulfillment need no third party. Asia: an official Taiwan distributor, B2B exports to Hong Kong, a Japan launch underway on Qoo10. Every product ships with a buyer-ready English dossier: IRB clinical summaries from three Korean institutes, full INCI lists, and safety data. Your regulatory team starts halfway done.